Assessment of Lipids Profile in Primary Brain Tumor Disease
تم أرسال البحث الثاني المكمل لدراسة التغيرات الكيمياوية في سرطان الدماغ الاولي
Background: Primary brain tumors (PBT) are classified according to the tissue of phylogenic origin. Tumors arising from the neuroepithelium encompass a subgroup of neoplasms collectively referred to as “Gliomas”. Of this subgroup; astrocytomas are by far the most common. The values of many biochemical parameters undergo changes to a certain degree in neoplastic conditions; serum lipids are some of those whose levels may alter.
Design and Aims of the study: a prospective study to investigate the serum lipid profile of a group of patients suffering from primary brain tumours (PBT) and to compare it with healthy volunteers.
Patients and methods: This study had been conducted between November 2013 and October 2015. Patients were evaluated by full medical history to exclude any existing systemic disease that may affect the parameters to be diagnosed, particularly diabetes, liver disease, renal disease and chronic drug intake; otherwise the patient would have been excluded from the study.
One hundred seven patients diagnosed clinically and histologically as a primary brain tumor. Out of the 107 patients suffering from primary brain tumors with an age range 2-75 years (mean 35, the standard SD ± 19), 56 were males (52.3%), and 51 were females (47.6%). The most affected age group was 31-40 years (17.75%), 89% of the patients were under the age of 60 years. Forty healthy subjects which were age and sex matched used as controls.
Results: The present study demonstrated a variable changes among circulating lipids. A highly significant increase in serum cholesterol of patients was noticed in comparison to that of normal subjects, the same finding was observed in serum low density lipoprotein (LDL). On the other hand, a high decrease in serum high density lipoprotein (HDL) and triglycerides (TG) was observed.
Conclusions and recommendations: The levels of the most common serum lipids do change in patients with PBT. Brain tumors cells may manufacture their requirements from lipids. Therapeutic measures may need to be implemente to correct such abnormality that may have untoward consequences on patients health.